Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Frycklund

Nurse Practitioner, Adult Health Willoughby, OH Nurse Practitioner

NPI 1366479693 CMS profile 11074316

38429 Lake Shore Blvd, Willoughby, OH 44094

Open in the dashboard

General payments

$12,499

558 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Frycklund of Willoughby, OH is reported in the CMS Open Payments database as having received $12,499 across 558 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118 2
2024 General $631 7
2023 General $2,520 111
2022 General $4,504 196
2021 General $4,726 242

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Frycklund
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Laura Frycklund were reported at $118. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Laura Frycklund Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $4,726 $138 $43–$438 $132
2022 $4,504 $165 $54–$494 $149
2023 $2,520 $178 $61–$549 $160
2024 $631 $186 $62–$575 $164
2025 $118 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,751 72 payments
  2. AbbVie, Inc. $1,416 81 payments
  3. Novo Nordisk Inc $1,358 51 payments
  4. Lilly USA, LLC $1,257 54 payments
  5. GlaxoSmithKline, LLC. $750 41 payments
  6. Pfizer Inc. $482 29 payments
  7. Amgen Inc. $419 18 payments
  8. Janssen Pharmaceuticals, Inc $416 17 payments
  9. Sanofi-Aventis U.S. LLC $361 12 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $336 24 payments
  11. Other $2,954 159 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,499 558 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $1,251 36 payments
  2. FARXIGA $1,057 28 payments
  3. RYBELSUS $747 41 payments
  4. Ozempic $615 41 payments
  5. VRAYLAR $558 26 payments
  6. TRELEGY ELLIPTA $540 34 payments
  7. MOUNJARO $529 14 payments
  8. JARDIANCE $500 30 payments
  9. Wegovy $435 5 payments
  10. XARELTO $416 17 payments
  11. Other $8,403 460 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

656

Median for Nurse Practitioner: 389

Drug cost

$95,785

Median for Nurse Practitioner: $21,885

Branded share of claims

28.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $25,650
Farxiga Dapagliflozin Propanediol Brand 35 $25,310
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 26 $20,292
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $13,100
Trintellix Vortioxetine Hydrobromide Brand 11 $5,062
Albuterol Sulfate Hfa Albuterol Sulfate Brand 31 $1,158
Rosuvastatin Calcium Generic 62 $936
Atorvastatin Calcium Generic 37 $452
Metformin Hcl Er Metformin Hcl Brand 17 $401
Metoprolol Succinate Generic 18 $391

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $246
$246 — —
Wegovy
  • Novo Nordisk Inc $213
$213 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $121
$121 — —
UBRELVY
  • AbbVie, Inc. $30
$30 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

558 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record